FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995601963> ?p ?o ?g. }

• W1995601963 endingPage "287" @default.
• W1995601963 startingPage "283" @default.
• W1995601963 abstract "Study objective Community-associated methicillin-resistant Staphylococcus aureus is now the leading cause of uncomplicated skin abscesses in the United States, and the role of antibiotics is controversial. We evaluate whether trimethoprim-sulfamethoxazole reduces the rate of treatment failures during the 7 days after incision and drainage and whether it reduces new lesion formation within 30 days. Methods In this multicenter, double-blind, randomized, placebo-controlled trial, we randomized adults to oral trimethoprim-sulfamethoxazole or placebo after uncomplicated abscess incision and drainage. Using emergency department rechecks at 2 and 7 days and telephone follow-up, we assessed treatment failure within 7 days, and using clinical follow-up, telephone follow-up, and medical record review, we recorded the development of new lesions within 30 days. Results We randomized 212 patients, and 190 (90%) were available for 7-day follow-up. We observed a statistically similar incidence of treatment failure in patients receiving trimethoprim-sulfamethoxazole (15/88; 17%) versus placebo (27/102; 26%), difference 9%, 95% confidence interval –2% to 21%; P=.12. On 30-day follow-up (successful in 69% of patients), we observed fewer new lesions in the antibiotic (4/46; 9%) versus placebo (14/50; 28%) groups, difference 19%, 95% confidence interval 4% to 34%, P=.02. Conclusion After the incision and drainage of uncomplicated abscesses in adults, treatment with trimethoprim-sulfamethoxazole does not reduce treatment failure but may decrease the formation of subsequent lesions. Community-associated methicillin-resistant Staphylococcus aureus is now the leading cause of uncomplicated skin abscesses in the United States, and the role of antibiotics is controversial. We evaluate whether trimethoprim-sulfamethoxazole reduces the rate of treatment failures during the 7 days after incision and drainage and whether it reduces new lesion formation within 30 days. In this multicenter, double-blind, randomized, placebo-controlled trial, we randomized adults to oral trimethoprim-sulfamethoxazole or placebo after uncomplicated abscess incision and drainage. Using emergency department rechecks at 2 and 7 days and telephone follow-up, we assessed treatment failure within 7 days, and using clinical follow-up, telephone follow-up, and medical record review, we recorded the development of new lesions within 30 days. We randomized 212 patients, and 190 (90%) were available for 7-day follow-up. We observed a statistically similar incidence of treatment failure in patients receiving trimethoprim-sulfamethoxazole (15/88; 17%) versus placebo (27/102; 26%), difference 9%, 95% confidence interval –2% to 21%; P=.12. On 30-day follow-up (successful in 69% of patients), we observed fewer new lesions in the antibiotic (4/46; 9%) versus placebo (14/50; 28%) groups, difference 19%, 95% confidence interval 4% to 34%, P=.02. After the incision and drainage of uncomplicated abscesses in adults, treatment with trimethoprim-sulfamethoxazole does not reduce treatment failure but may decrease the formation of subsequent lesions." @default.
• W1995601963 created "2016-06-24" @default.
• W1995601963 creator A5005120675 @default.
• W1995601963 creator A5008464930 @default.
• W1995601963 creator A5015576120 @default.
• W1995601963 creator A5019605359 @default.
• W1995601963 creator A5032964679 @default.
• W1995601963 creator A5035863992 @default.
• W1995601963 creator A5050496363 @default.
• W1995601963 creator A5053884943 @default.
• W1995601963 creator A5065982905 @default.
• W1995601963 creator A5074351268 @default.
• W1995601963 creator A5077835181 @default.
• W1995601963 creator A5088356893 @default.
• W1995601963 creator A5091775068 @default.
• W1995601963 date "2010-09-01" @default.
• W1995601963 modified "2023-10-10" @default.
• W1995601963 title "Randomized Controlled Trial of Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Abscesses in Patients at Risk for Community-Associated Methicillin-Resistant Staphylococcus aureus Infection" @default.
• W1995601963 cites W1976018911 @default.
• W1995601963 cites W2014648145 @default.
• W1995601963 cites W2026847949 @default.
• W1995601963 cites W2049063050 @default.
• W1995601963 cites W2079750073 @default.
• W1995601963 cites W2142220903 @default.
• W1995601963 cites W2143134882 @default.
• W1995601963 cites W2148133809 @default.
• W1995601963 cites W2158062169 @default.
• W1995601963 cites W2268708037 @default.
• W1995601963 doi "https://doi.org/10.1016/j.annemergmed.2010.03.002" @default.
• W1995601963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20346539" @default.
• W1995601963 hasPublicationYear "2010" @default.
• W1995601963 type Work @default.
• W1995601963 sameAs 1995601963 @default.
• W1995601963 citedByCount "152" @default.
• W1995601963 countsByYear W19956019632012 @default.
• W1995601963 countsByYear W19956019632013 @default.
• W1995601963 countsByYear W19956019632014 @default.
• W1995601963 countsByYear W19956019632015 @default.
• W1995601963 countsByYear W19956019632016 @default.
• W1995601963 countsByYear W19956019632017 @default.
• W1995601963 countsByYear W19956019632018 @default.
• W1995601963 countsByYear W19956019632019 @default.
• W1995601963 countsByYear W19956019632020 @default.
• W1995601963 countsByYear W19956019632021 @default.
• W1995601963 countsByYear W19956019632022 @default.
• W1995601963 countsByYear W19956019632023 @default.
• W1995601963 crossrefType "journal-article" @default.
• W1995601963 hasAuthorship W1995601963A5005120675 @default.
• W1995601963 hasAuthorship W1995601963A5008464930 @default.
• W1995601963 hasAuthorship W1995601963A5015576120 @default.
• W1995601963 hasAuthorship W1995601963A5019605359 @default.
• W1995601963 hasAuthorship W1995601963A5032964679 @default.
• W1995601963 hasAuthorship W1995601963A5035863992 @default.
• W1995601963 hasAuthorship W1995601963A5050496363 @default.
• W1995601963 hasAuthorship W1995601963A5053884943 @default.
• W1995601963 hasAuthorship W1995601963A5065982905 @default.
• W1995601963 hasAuthorship W1995601963A5074351268 @default.
• W1995601963 hasAuthorship W1995601963A5077835181 @default.
• W1995601963 hasAuthorship W1995601963A5088356893 @default.
• W1995601963 hasAuthorship W1995601963A5091775068 @default.
• W1995601963 hasConcept C118552586 @default.
• W1995601963 hasConcept C126322002 @default.
• W1995601963 hasConcept C141071460 @default.
• W1995601963 hasConcept C142724271 @default.
• W1995601963 hasConcept C168563851 @default.
• W1995601963 hasConcept C204787440 @default.
• W1995601963 hasConcept C27081682 @default.
• W1995601963 hasConcept C2777035434 @default.
• W1995601963 hasConcept C2777052132 @default.
• W1995601963 hasConcept C2779425571 @default.
• W1995601963 hasConcept C2779489039 @default.
• W1995601963 hasConcept C2780724011 @default.
• W1995601963 hasConcept C2780728791 @default.
• W1995601963 hasConcept C2780879076 @default.
• W1995601963 hasConcept C44249647 @default.
• W1995601963 hasConcept C501593827 @default.
• W1995601963 hasConcept C523546767 @default.
• W1995601963 hasConcept C54355233 @default.
• W1995601963 hasConcept C71924100 @default.
• W1995601963 hasConcept C86803240 @default.
• W1995601963 hasConcept C89423630 @default.
• W1995601963 hasConceptScore W1995601963C118552586 @default.
• W1995601963 hasConceptScore W1995601963C126322002 @default.
• W1995601963 hasConceptScore W1995601963C141071460 @default.
• W1995601963 hasConceptScore W1995601963C142724271 @default.
• W1995601963 hasConceptScore W1995601963C168563851 @default.
• W1995601963 hasConceptScore W1995601963C204787440 @default.
• W1995601963 hasConceptScore W1995601963C27081682 @default.
• W1995601963 hasConceptScore W1995601963C2777035434 @default.
• W1995601963 hasConceptScore W1995601963C2777052132 @default.
• W1995601963 hasConceptScore W1995601963C2779425571 @default.
• W1995601963 hasConceptScore W1995601963C2779489039 @default.
• W1995601963 hasConceptScore W1995601963C2780724011 @default.
• W1995601963 hasConceptScore W1995601963C2780728791 @default.
• W1995601963 hasConceptScore W1995601963C2780879076 @default.
• W1995601963 hasConceptScore W1995601963C44249647 @default.
• W1995601963 hasConceptScore W1995601963C501593827 @default.
• W1995601963 hasConceptScore W1995601963C523546767 @default.

• next